UY33203A - Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno - Google Patents
Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígenoInfo
- Publication number
- UY33203A UY33203A UY0001033203A UY33203A UY33203A UY 33203 A UY33203 A UY 33203A UY 0001033203 A UY0001033203 A UY 0001033203A UY 33203 A UY33203 A UY 33203A UY 33203 A UY33203 A UY 33203A
- Authority
- UY
- Uruguay
- Prior art keywords
- mitigates
- suppresses
- targer
- originated
- peripheral nerve
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Abstract
La presente invención provee un medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno, caracterizado porque comprende un compuesto de fórmula (I) o un compuesto de fórmula (II) o un compuesto de fórmula (III).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010015935 | 2010-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33203A true UY33203A (es) | 2011-08-31 |
Family
ID=43770309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033203A UY33203A (es) | 2010-01-27 | 2011-01-26 | Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno |
Country Status (41)
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013253408C1 (en) | 2012-04-27 | 2016-04-21 | Nagoya Industrial Science Research Institute | Trans-2-decenoic acid derivative and drug containing same |
CA2933883A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
CA2985325C (en) | 2015-05-08 | 2023-09-26 | Takeda Pharmaceutical Company Limited | Cyclic compounds for inhibition of toll-like receptor 4 |
MX2017016353A (es) | 2015-06-17 | 2018-05-02 | Genentech Inc | Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos. |
BR112019004520A2 (pt) * | 2016-09-09 | 2019-05-28 | Takeda Pharmaceuticals Co | composto, medicamento, métodos para inibição de um receptor toll-like 4 e para prevenção ou tratamento de uma doença, e, uso do composto. |
EP3679925A4 (en) * | 2017-09-07 | 2021-04-21 | Shenzhen Salubris Pharmaceuticals Co. Ltd | PHARMACEUTICAL COMPOSITION OF DOCETAXEL CONJUGATE AND METHOD OF PREPARATION |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
WO1987004170A1 (en) | 1986-01-09 | 1987-07-16 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
WO1988005083A1 (en) | 1986-12-24 | 1988-07-14 | Whitehead Institute For Biomedical Research | Method of inducible gene expression |
WO1989007614A1 (en) | 1988-02-12 | 1989-08-24 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
CA1341606C (en) | 1988-03-01 | 2010-06-08 | Whitehead Institute For Biomedical Research | Activation of nf-kb precursor |
WO1990011761A1 (en) | 1989-03-31 | 1990-10-18 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5158883A (en) | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
US5059712A (en) | 1989-09-13 | 1991-10-22 | Cornell Research Foundation, Inc. | Isolating aminoarginine and use to block nitric oxide formation in body |
EP0557290A1 (en) | 1990-08-23 | 1993-09-01 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
WO1992017168A1 (en) | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
EP0581856B1 (en) | 1991-04-19 | 1999-07-14 | The Children's Medical Center Corporation | Method of preventing nmda receptor complex-mediated neuronal damage |
US6071876A (en) | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
MX9709442A (es) * | 1995-06-07 | 1998-02-28 | Sugen Inc | Metodo y composiciones para la inhibicion de interacciones entre proteina adaptadora y tirosinquinasa. |
US20020086368A1 (en) | 1997-10-17 | 2002-07-04 | Genentech Inc | Human toll homologues |
US20020052019A1 (en) | 1997-11-13 | 2002-05-02 | Genentech Inc | Human toll homologue |
US20030032090A1 (en) | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
JP4319348B2 (ja) | 1997-10-17 | 2009-08-26 | ジェネンテック・インコーポレーテッド | ヒトトール相同体 |
JP2002507384A (ja) | 1997-11-25 | 2002-03-12 | プリンストン ユニヴァーシティー | アデノウイルスベクターの製造方法、それによって製造したベクターおよびその使用 |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US20040072138A1 (en) | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
US20080275104A1 (en) | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
EP1524263A1 (en) | 1998-03-09 | 2005-04-20 | Takeda Pharmaceutical Company Limited | prodrugs containing cycloalkene derivatives |
KR20070095416A (ko) | 1999-08-06 | 2007-09-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 치환 방향환 화합물, 그의 제조법 및 용도 |
SE9903930D0 (sv) * | 1999-10-29 | 1999-10-29 | Astra Pharma Inc | Novel compounds and a novel process for their preparation |
DE60124504T2 (de) | 2000-02-04 | 2007-09-20 | Takeda Pharmaceutical Co. Ltd. | Stabile emulsionszubereitungen |
AU6488901A (en) | 2000-05-25 | 2001-12-03 | Schering Corp | Human receptor proteins; related reagents and methods |
CA2685447C (en) | 2000-08-10 | 2013-05-28 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
EP1334966B1 (en) | 2000-10-18 | 2011-05-04 | Takeda Pharmaceutical Company Limited | Process for preparation of optically active sulfonamides and intermediates for their synthesis |
CA2398613C (en) | 2000-11-30 | 2006-09-12 | Tokuyama Corporation | Substrate and production method therefor |
WO2002045750A1 (fr) | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Medicaments combines |
WO2003013513A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Stable emulsion composition |
US20060058288A1 (en) | 2002-04-08 | 2006-03-16 | Masayuki Ii | Severe sepsis preventive therapeutic agent |
US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
US20040259790A1 (en) | 2003-01-30 | 2004-12-23 | Bali Pulendran | Methods for identifying and administering agents that bias the immune response via dendritic cells |
WO2004075865A2 (en) | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
JP2006523452A (ja) | 2003-03-25 | 2006-10-19 | スリーエム イノベイティブ プロパティズ カンパニー | 共通のToll様受容体を通じて媒介される細胞活性の選択的活性化 |
US20050059072A1 (en) | 2003-09-17 | 2005-03-17 | 3M Innovative Properties Company | Selective modulation of TLR gene expression |
WO2005062854A2 (en) | 2003-12-19 | 2005-07-14 | University Of Cincinnati | Polyamides for nucleic acid delivery |
TWI462745B (zh) | 2005-04-28 | 2014-12-01 | Takeda Pharmaceutical | 安定的乳化組成物 |
EP2308510B1 (en) | 2005-06-03 | 2016-03-16 | Ono Pharmaceutical Co., Ltd. | Agent for regeneration and/or protection of nerves |
US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
WO2007091790A1 (en) | 2006-02-07 | 2007-08-16 | Korea Institute Of Radiological & Medical Sciences | A composition for treating damage of central or peripheral nerve system |
EP1996935B1 (en) | 2006-02-23 | 2011-09-14 | Yale University | Drug resistance to plant alkaloids based upon myd88 status in a cell and methods of inhibiting signaling through the tlr-4:myd88 pathway |
US7943588B2 (en) | 2006-03-28 | 2011-05-17 | Trustees Of Dartmouth College | Method for preventing or treating neuropathic pain |
JP4962982B2 (ja) | 2006-03-30 | 2012-06-27 | 国立大学法人広島大学 | スクリーニング方法 |
US20090062355A1 (en) | 2006-04-20 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Pharmaceutical Product |
US20090105314A1 (en) | 2006-05-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Pharmaceutical Agent |
WO2008004673A1 (fr) | 2006-07-07 | 2008-01-10 | Takeda Pharmaceutical Company Limited | Dérives de cycloalkène, procédé de production des dérivés et utilisation de ceux-ci |
EP1882687A1 (en) * | 2006-07-27 | 2008-01-30 | Amorepacific Corporation | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same |
WO2008112887A1 (en) | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
WO2009059050A2 (en) | 2007-10-30 | 2009-05-07 | The Regents Of The University Of Colorado | Tlr modulators and methods for using the same |
JP2011513483A (ja) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
JP5238381B2 (ja) | 2008-07-07 | 2013-07-17 | スタンレー電気株式会社 | 照明用車両用灯具 |
US8642614B2 (en) | 2009-09-23 | 2014-02-04 | The Regents Of The University Of Colorado, A Body Corporate | Toll-like receptor modulators and uses thereof |
-
2011
- 2011-01-26 CN CN201510072433.2A patent/CN104744321A/zh active Pending
- 2011-01-26 KR KR1020127021846A patent/KR20120118044A/ko active IP Right Grant
- 2011-01-26 MY MYPI2012003414A patent/MY163936A/en unknown
- 2011-01-26 JP JP2012533416A patent/JP6131046B2/ja active Active
- 2011-01-26 HU HUE11705047A patent/HUE027310T2/en unknown
- 2011-01-26 SG SG10201503402XA patent/SG10201503402XA/en unknown
- 2011-01-26 CN CN201180015681.3A patent/CN102821763B/zh not_active Expired - Fee Related
- 2011-01-26 GE GEAP201112845A patent/GEP20166441B/en unknown
- 2011-01-26 CA CA2788150A patent/CA2788150C/en not_active Expired - Fee Related
- 2011-01-26 UY UY0001033203A patent/UY33203A/es not_active Application Discontinuation
- 2011-01-26 AR ARP110100247A patent/AR080024A1/es unknown
- 2011-01-26 EP EP11705047.6A patent/EP2528598B1/en active Active
- 2011-01-26 MX MX2012008514A patent/MX2012008514A/es not_active Application Discontinuation
- 2011-01-26 MA MA35162A patent/MA34014B1/fr unknown
- 2011-01-26 SG SG2012051967A patent/SG182522A1/en unknown
- 2011-01-26 DK DK11705047.6T patent/DK2528598T3/en active
- 2011-01-26 BR BR112012018434A patent/BR112012018434A2/pt not_active IP Right Cessation
- 2011-01-26 PE PE2012001062A patent/PE20121694A1/es not_active Application Discontinuation
- 2011-01-26 AU AU2011211294A patent/AU2011211294B2/en not_active Ceased
- 2011-01-26 WO PCT/JP2011/052077 patent/WO2011093512A1/en active Application Filing
- 2011-01-26 PT PT117050476T patent/PT2528598E/pt unknown
- 2011-01-26 PL PL11705047T patent/PL2528598T3/pl unknown
- 2011-01-26 RS RS20160076A patent/RS54591B1/en unknown
- 2011-01-26 NZ NZ601635A patent/NZ601635A/xx not_active IP Right Cessation
- 2011-01-26 ES ES11705047.6T patent/ES2560215T3/es active Active
- 2011-01-26 UA UAA201210137A patent/UA109540C2/uk unknown
- 2011-01-26 US US13/574,848 patent/US20130046000A1/en not_active Abandoned
- 2011-01-26 ME MEP-2016-31A patent/ME02364B/me unknown
- 2011-01-26 SI SI201130755T patent/SI2528598T1/sl unknown
- 2011-01-26 TW TW100102774A patent/TWI481401B/zh not_active IP Right Cessation
- 2011-01-26 EA EA201290697A patent/EA201290697A1/ru unknown
-
2012
- 2012-07-17 TN TNP2012000364A patent/TN2012000364A1/en unknown
- 2012-07-23 IL IL221066A patent/IL221066A/en not_active IP Right Cessation
- 2012-07-25 DO DO2012000209A patent/DOP2012000209A/es unknown
- 2012-07-26 CL CL2012002079A patent/CL2012002079A1/es unknown
- 2012-07-27 ZA ZA2012/05681A patent/ZA201205681B/en unknown
- 2012-08-07 CR CR20120412A patent/CR20120412A/es unknown
- 2012-08-17 CO CO12140288A patent/CO6592110A2/es not_active Application Discontinuation
- 2012-08-27 EC ECSP12012126 patent/ECSP12012126A/es unknown
-
2013
- 2013-04-10 HK HK13104374.3A patent/HK1177423A1/zh not_active IP Right Cessation
- 2013-08-20 US US13/971,159 patent/US8901171B2/en not_active Expired - Fee Related
-
2014
- 2014-10-28 US US14/525,576 patent/US20150051256A1/en not_active Abandoned
-
2015
- 2015-04-02 US US14/676,947 patent/US20150203464A1/en not_active Abandoned
-
2016
- 2016-02-15 HR HRP20160165TT patent/HRP20160165T1/hr unknown
- 2016-02-19 US US15/047,965 patent/US20160166526A1/en not_active Abandoned
- 2016-03-04 CY CY20161100189T patent/CY1117268T1/el unknown
- 2016-03-18 JP JP2016056186A patent/JP2016175903A/ja active Pending
- 2016-04-12 SM SM201600103T patent/SMT201600103B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501385A1 (en) | Autotaxin inhibitors | |
SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
MX2015011897A (es) | Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
EA201890915A1 (ru) | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma | |
TN2014000319A1 (en) | Imidazopyrrolidinone compounds | |
MX371279B (es) | Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo. | |
UY33203A (es) | Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno | |
MY166045A (en) | Abeta antibody formulation | |
PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
UA110213C2 (en) | Use of sigma-ligand induced opioid hyperalgesia | |
EA201590863A1 (ru) | Пролекарства с минимальной токсичностью | |
BR112014018135A8 (pt) | Produto farmacêutico e uso do produto farmacêutico | |
CO7101239A2 (es) | Composiciones derivadas de la quitosana | |
UY35253A (es) | Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o una enfermedad cogniti vos, neurodegenerativos o neuronales | |
IN2014DN07913A (es) | ||
BR112018002763A2 (pt) | método para cicatrização de ferimentos | |
TR201906539T4 (tr) | Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi. | |
EA201692531A1 (ru) | Способы лечения инфекций | |
GB201206984D0 (en) | New therapeutic use | |
IN2013MU02469A (es) | ||
WO2013049280A3 (en) | Sphingosine analogs, compositions, and methods related thereto | |
BR112015001515A2 (pt) | compostos terapêuticos | |
UA82243U (ru) | Соединение n-пара-бромфенил-3(-уридин-6'-амино)-сукцинимид с потенциальными физиологическими свойствами | |
TH152467A (th) | ยาสำหรับการบำบัดโรคด้านหน้าของตาซึ่งประกอบรวมด้วยรีบามิไพด์ และเอเจนท์การคงน้ำตาไว้ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20191209 |